DUSP18

Across TCGA pan-cancer cohorts, DUSP18 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated DUSP18 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher DUSP18 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DUSP18 expression acts as an unfavorable survival marker.

LIHC and BLCA are the cancer types where DUSP18 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.144	0.688	.013	9	view →
BLCA	DFS	Median	All	0.153	0.615	.024	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

DUSP18–LIHC (OS)

Open the LIHC breakdown →